– Our website is undergoing an update –
The information currently available on the website concerns the previous 2018-2022 labeling.
WHO ARE WE
The CARPEM SIRIC is one of 8 integrated cancer research sites accredited by INCa for the period 2023-2027.
Since 2013, we develop precision medicine for solid and hematological tumors. It brings together the fundamental, translational and clinical oncology research expertise of the Paris CARPEM Cancer Institute (GHU APHP.Centre – Université Paris Cité, INSERM), the first Comprehensive Cancer Center of APHP to be accredited by OECI. Our research project, entitled “CARPEM3: CAncer Research in multiple dimensions to accelerate PrEcision Medicine”, aims to accelerate the implementation of precision medicine to improve the care of cancer patients.
22 RESEARCH TEAMS
12 CLINICAL TEAMS
OUR 3 programs
Multiscale approaches to tumors to identify factors influencing patient survival
This program aims to understand how interactions between tumor cells and their environment influence tumorigenesis and response to treatment, through multidimensional analyses.
Implementing biomarkers in the clinic - from single marker to composite marker
This program aims to implement biomarkers in routine care, with the potential to modify the management of cancer patients.
Implementation of a program to involve patients and their families in translational research
This program aims to strengthen the involvement of patients and their families in the translational research carried out by SIRIC CARPEM.
We federate 12 clinical teams of Institut du Cancer Paris CARPEM (GHU APHP.Centre – Université Paris Cité)
22 research teams in the largest Parisian institutes are dedicated to cancer research.